The A673T variant of the amyloid precursor protein (APP) protects against Alzheimer disease (AD). Results: A673T reduces BACE1 processing of APP by decreasing catalytic turnover and reduces amyloid-␤(1-42) aggregation. Conclusion: A673T APP protects against AD primarily by reducing A␤ production and also by reducing aggregation. Significance: The biochemical nature of the A673T protective mutation provides insight into AD development.
Genetic studies of Alzheimer disease (AD) 5 have helped shape our current understanding of disease etiology. For example, mutations in presenilin1 (PSEN1) and presenilin 2 (PSEN2), enzymes involved in the processing of APP, have been found in autosomal dominant familial cases of AD (2) (3) (4) . More recently, PSEN1 mutations have also been identified in some sporadic cases of late onset AD (5) . Numerous disease-associated mutations in the APP gene itself have also been identified. Many of these mutations cluster at or near the ␤or ␥-proteolytic sites, favoring either the overproduction of total amyloid-␤ (A␤) (6 -8) or an increased ratio of the pro-aggregating A␤(1-42) species relative to A␤(1-40) (9 -12) . In other instances, mutations within the A␤ peptide promote an increased propensity for aggregation (7, 13, 14) . Together, these genetic findings provide strong support for the amyloid hypothesis of AD, which postulates that an imbalance in the production and clearance of A␤ initiates a cascade of amyloid accumulation, neurotoxicity, and neurodegeneration (15) .
Identification of genetic variants that protect from AD can be equally informative in revealing the mechanisms underlying disease biology, and they could guide therapeutic approaches to block disease development or progression. Recently, we reported a low frequency variant in the APP gene (rs63750847-A) that confers significant protection against AD (1). This variant results in an alanine-to-threonine substitution at position 673 in the APP gene (A673T), adjacent to the ␤-cleavage site. Our primary characterization of the A673T variant demonstrated that this mutation made APP a less favorable substrate for BACE1, resulting in reduced levels of A␤ production (1) . However, the A673T substitution lies within the A␤ peptide and thus could also alter the properties of the A␤ peptide itself. Here, we examine the effects of this variant on the kinetics of APP processing by BACE1, and additionally, we evaluate the impact of this substitution on A␤ aggregation and biological activity, including microglial uptake and cellular toxicity. Our results provide further support for reduced ␤-site cleavage of the A673T APP variant and additionally reveal modest alterations in A␤(1-42) peptide aggregation, as assessed using synthetic peptides.
EXPERIMENTAL PROCEDURES
Cellular APP Cleavage Assays-Human APP695 cDNAs encoding WT APP, APP A673T, or APP A673V were transfected into 293T cells maintained in DMEM ϩ 10% FBS as described previously (1) . After 4 days in vitro (DIV), cells were lysed using RIPA buffer with Complete Protease Inhibitor Mixture (Roche Applied Science) to assay for ␤-CTFs. The cell supernatant was also collected to confirm reduced A␤ production. Dissociated cortical neuron cultures (plated at 2.5 ϫ 10 4 cells/well in a 96-well plate) were prepared from E16.5 C57BL/6J mice. Prior to plating, cells were nucleofected with Amaxa (Lonza, Basel, Switzerland) with cDNAs encoding the same human APP695 constructs described above or ␤-galactosidase (control). After 6 DIV, cells were incubated with 50 l/well fresh cell medium for 24 h. The medium was collected and used for A␤ ELISA measurements (see below). For both cell types, the efficiency of transfection across different constructs was compared by lysing a separate well of cells with Ambion Cells-to-C T TM (Invitrogen) to assess APP RNA levels by quantitative PCR. Human cortical neurons (catalogue no. DDP-NC-1.0) derived from control donor iPS cells (clone ID 01279.107), the isogenic APP-A673V iPS cells (01279.A32), and the isogenic APP-A673T iPS cells (01279.A27) were ordered from Cellular Dynamics International Inc. (Madison, WI). Human iPSC-derived neurons were plated in 8-well chamber slide (BD 354688) at a density of 1 ϫ 10 5 cells/well. The culture slides were prepared with poly-D-lysine and laminin following the Cellular Dynamics International user's guide. Half of the conditioned media was replaced with fresh warm media every 2 days. To confirm APP expression, cells were fixed with 4% paraformaldehyde, 4% sucrose, permeabilized with 0.1% Triton X-100, and blocked in 2% BSA/PBS. Cells were stained with rabbit monoclonal anti-APP clone Y188 (Abcam, Cambridge, MA) and mouse anti-MAP2 clone 5F9 (Abcam, Cambridge, MA) in 2% BSA/PBS for 2 h. After washing, the secondary goat anti-mouse IgG AlexaFluor488 antibody A10680 (Invitrogen) and goat anti-rabbit IgG AlexaFluor568-conjugated antibody A11036 (Invitrogen) were applied for 30 min at 1:200 in 2% BSA/PBS. Media were harvested after 4 DIV for sAPP analysis and after 14 DIV for A␤ measurements. Experiments were performed at least three times, with technical triplicates in each experiment.
␤-CTF Analysis-Cell lysates from transfected 293T cells were run on 4 -12% Novex BisTris gels (Invitrogen) for SDS-PAGE analysis. ␤-CTFs were detected by incubating blots with the C-terminal polyclonal APP antibody A8717 (Sigma) or the monoclonal mid-domain APP antibody 6E10 (Covance, Dedham, MA). Imaging was performed on the Bio-Rad VersaDoc gel imaging system. ␤-CTFs were quantified using an ELISA from IBL International (catalogue no. 27776, Hamburg, Germany) following the manufacturer's guidelines.
A␤ and sAPP Immunoassays-A␤40 and A␤42 peptides were measured from transfected HEK 293 and primary neuron cell supernatants by sandwich ELISAs as described previously (1) . Briefly, rabbit polyclonal antibody specific for the C terminus of A␤40 or A␤42 (Millipore, Bedford, MA) was coated onto plates, and biotinylated anti-A␤ monoclonal antibody 6E10 (Covance, Dedham, MA) was used for detection. The assays had a lower limit of quantification values of 6.24 pg/ml for A␤40 and 18.76 pg/ml for A␤42. For iPSC-derived neurons, A␤40 and A␤42 peptides were measured from cell supernatants using a sandwich electro-chemiluminescence immunoassay (Meso Scale Discovery catalogue no. K15148E, Gaithersburg, MD). Cell supernatants from all cell types were also assayed for sAPP cleavage products by using a sAPP␣/sAPP␤ multiplex kit (Meso Scale Discovery catalogue no. K15120E).
TR-FRET Cleavage of WT and Swedish APP(662-688) Substrates-N-terminally biotinylated peptide substrates containing either WT (biotin-KTEEISEVKMDAEFRHDSGY-EVHHQKL), A673T (biotin-KTEEISEVKMDTEFRHDSGYE-VHHQKL), or A673V (biotin-KTEEISEVKMDVEFRHDSGY-EVHHQKL) and similar peptides with the Swedish mutation in combination (biotin-KTEEISEVNLDAEFRHDSGYEVHH-QKL, biotin-KTEEISEVNLDTEFRHDSGYEVHHQKL, and biotin-KTEEISEVNLDVEFRHDSGYEVHHQKL) were custom-synthesized by American Peptide Co. Streptavidin-d2 (SA-d2) and anti-A␤ monoclonal antibody 6E10 (Covance, Dedham, MA) labeled with europium cryptate (6E10-Eu) were purchased from CisBio (Bedford, MA). We previously demonstrated that the A673T mutation does not interfere with detection by the 6E10 antibody (1) . Enzyme reactions were carried out in 384-well black low volume proxiplate (PerkinElmer Life Sciences) with 50 nM recombinant human BACE1 ECD (Genentech) and 5 M peptide substrate in the reaction buffer (50 mM sodium acetate, pH 4.4, 0.1% CHAPS, 0.1% BSA) at ambient temperature for up to 48 h for non-Swedish peptides and up to 30 min for peptides containing the Swedish mutation. The enzyme reactions were quenched with the addition of equal volume stop buffer (200 mM Tris, pH 8, 0.1% CHAPS, 0.1% BSA). Peptides in the reactions were then further diluted to 300 nM prior to the addition of an equal volume of detection reagent (10 nM anti-A␤ 6E10-Eu, 75 nM SA-d2, 800 mM KF, 200 mM Tris, pH 8, 0.1% CHAPS, 0.1% BSA), and the mixture was incubated at ambient temperature for 1 h. The plates were measured in an EnVision (PerkinElmer Life Sciences) reader, and the TR-FRET ratio with 320 nm excitation, 615 nm donor emission, and 665 nm acceptor emission was calculated as (em 665 /em 615 )⅐Z, where Z ϭ 5000. The reaction progress curves were determined by subtracting background signal at time 0 for each reaction, and reaction rates (min Ϫ1 ) were calculated from linear fits using GraphPad Prism (Sunnyvale, CA).
FRET K m Determination with Short APP(668-675) Peptides-Three FRET peptide substrates, containing WT APP amino acid sequence 668 -675 (E(EDANS)EVKMDAEFK(Dabcyl)-NH 2 ), A673T (E(EDANS)EVKMDTEFK(Dabcyl) NH 2 ), or A673V (E(EDANS)EVKMDVEFK(Dabcyl)NH 2 ) were custom-synthesized by American Peptide Co. (Sunnyvale, CA). Each peptide was conjugated with a fluorescent donor molecule EDANS at the N terminus and a quencher molecule Dabcyl at the C terminus. The peptide substrates were titrated up to 100 M in reaction buffer (50 mM sodium acetate, pH 4.4, 0.1% CHAPS, 0.1% BSA), and the proteolytic reaction was carried out using 50 nM BACE1 at ambient temperature. The enzyme reactions were quenched at various time points up to 48 h with the addition of equal volume stop buffer (200 mM Tris, pH 8, 0.1% CHAPS, 0.1% BSA). Fluorescence intensity at 490 nm with excitation at 340 nm was measured using Tecan M1000 fluorescence reader (Tecan, Männedorf, Switzerland), and the total fluorescence intensity gain was determined by subtracting background fluorescence at time 0 from the fluorescence intensity of each reaction mixture at different time points. Reaction rates (min Ϫ1 ) were calculated from linear fits of the reaction progress curves, and the Michaelis-Menten equation was applied to determine K m and V max values using GraphPad Prism (Sunnyvale, CA).
IC 50 Determination of APP Peptide A673 Variants in FRET Cleavage Assay-FRET peptide substrate with the Swedish mutation (Rh-EVNLDAEFK-Quencher) was obtained from Invitrogen. Enzyme reactions were carried out with 50 nM BACE1, 150 nM FRET peptide substrate with Swedish mutation, and up to 100 M biotinylated peptide in reaction buffer (50 mM sodium acetate, pH 4.4, 0.1% CHAPS, 0.1% BSA) at ambient temperature. Fluorescence intensity (530 nm excitation, 590 nm emission) was continuously monitored for 85 min on a Tecan M1000 fluorescence reader. Initial background signal at each peptide concentration was subtracted from each reaction time. Reaction rates (min Ϫ1 ) were calculated from linear fits, and peptide IC 50 values were generated using a fourparameter nonlinear fit in GraphPad Prism.
Aggregation Kinetics as Measured by Thioflavin-T Fluorescence-The synthetic peptides (AnaSpec, Fremont, CA) were disaggregated by dissolution in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP), followed by evaporation under a stream of nitrogen. Immediately before analysis, the peptide film was thoroughly dissolved in 10 mM NaOH, neutralized in an equal volume of 100 mM sodium phosphate buffer, pH 7.4, and filtered with a 0.2-m syringe filter. UV absorbance of the solution at 280 nm was measured, and the peptide concentration was determined using the respective theoretical extinction coefficient and adjusted to 1.0 mg/ml with 5 mM NaOH, 50 mM sodium phosphate buffer, pH 7.4. The redissolved and adjusted peptide solution was transferred into a well of the 96-well plate containing an equal volume of 56 M thioflavin-T (ThT) in 2 mM NaN 3 , 50 mM phosphate buffer, pH 7.4. All data were recorded with a Tecan Safire II reader and black, clear-bottom, and sealed 96-well plates (Corning Glass) in bottom-reading mode at 37°C. Kinetic reads were taken every 15 min (A␤(1-40)) or every 10 min (A␤(1-42) and A␤(1-42)/A␤(1-40) mixtures). ThT was excited at 450 nm, and the fluorescence emission signal was read at 490 nm. For each experiment, traces of the mean of three technical replicates were plotted using GraphPad Prism 5, and error bars of the final point indicate standard deviation.
Microglial A␤ Uptake Assay and Immunocytochemistry-Primary microglia were prepared from P2 C57BL/6J mice at a density of 6 ϫ 10 4 cells per well in 8-well poly-D-lysine-coated chamber slides, and the A␤ uptake assay was performed 48 h later. A␤(1-40) and A␤(1-42) peptides were custom-synthesized by rPeptide (Bogart, GA) and prepared as oligomers according to Stine et al. (16) with the following modifications: peptides were resuspended in 1:10 v/v 1% NH 4 OH/HFIP to 20 M and lyophilized overnight. Lyophilized peptides were resuspended in anhydrous dimethyl sulfoxide (DMSO) D2650 (Sigma) to 5 mM and immediately diluted to 100 M in ice-cold cell culture medium (phenol red-free Ham's F-12), vortexed for 30 s, and incubated at 4°C for 24 h. Peptides were aliquoted and stored at Ϫ80°C. 1 M of A␤(1-40) or A␤(1-42) peptides was added to primary microglial cultures. After 90 min, microglia were washed three times with cold PBS, immediately fixed in 4% paraformaldehyde, 4% sucrose. Cells were then blocked in 2% BSA/PBS and permeabilized in 0.1% Triton X-100 (Sigma catalogue no. 93426-250 ml) for 20 min and stained with mouse anti-A␤ (Covance, Dedham, MA, catalogue no. SIG-39320) at 1:500 and rabbit anti-Iba1 019 -19741 (Wako, Osaka, Japan) at 1:200 in 2% BSA/PBS for 2 h. After washing, the secondary goat anti-mouse IgG AlexaFluor488 antibody A10680 (Invitrogen) and goat anti-rabbit IgG AlexaFluor568-conjugated antibody A11036 (Invitrogen) were applied for 30 min at 1:200 in 2% BSA/PBS. Immunostained cells were analyzed on a Zeiss 200 M confocal microscope (Thornwood, NY) and processed with Photoshop CS5. To quantify intracellular A␤ uptake by microglia, the area corresponding to intracellular A␤ was delineated using Iba1 staining, and the raw integrated signal intensity was determined per microglia. The quantification was performed using ImageJ software, and values are represented in arbitrary units. 10 -20 cells from each condition were quantified in each of three independent experiments, and data from the three experiments were then averaged.
Cellular Toxicity Assays-Cortical neurons were isolated from E16.5 C57BL/6J mice and plated at a density of 3.5 ϫ 10 4 cells per well in 96-well poly-D-lysine-coated plates (BD Biosciences). At 6 DIV, cells were treated with freshly prepared A␤(1-40) or A␤(1-42) WT, A2T, or A2V synthetic peptides (rPeptide, Bogart, GA) or vehicle. The peptides were initially resuspended in NH 4 OH/HFIP and lyophilized as described for microglial experiments. Lyophilized peptides were then dissolved in DMSO to generate a 5 mM stock and immediately diluted in culture medium and incubated with cells. After 72 h, cell viability was assessed using the Cell Titer Glo assay, following the manufacturer's instructions (Promega, Madison, WI). Experiments were performed three times, with technical triplicates per construct in each experiment.
RESULTS

A673T Variant Reduces BACE1 Cleavage of APP in Primary
Neurons-We previously reported that the A673T variant of APP decreases production of the BACE1 cleavage product sAPP␤ and both of the amyloidogenic peptides A␤40 and A␤42 by ϳ40% when overexpressed in HEK 293 cells (1) . To extend these findings, we looked at the production of another APP BACE1 cleavage product, the ␤-CTF, C99. We transfected HEK comparison, we also examined two pathogenic APP variants, A673V and K670N/M671L (Swedish mutation), which have both been shown to increase A␤ and ␤-CTF production. We first examined ␤-CTF production by Western blot analysis of cell lysates using two antibodies as follows: A8717, which detects both ␣and ␤-CTF, and 6E10, which detects only ␤-CTF ( Fig. 1A) . CTFs were readily detected in APP-transfected cells and absent in control GFP-transfected cells. As expected, higher levels of ␤-CTF were seen in cells expressing the pathogenic APP variants A673V or K670N/M671L; conversely, APP A673T reduced ␤-CTF levels. To quantify these changes, we used a ␤-CTF ELISA to analyze these cell lysates. A673T reduced ␤-CTF levels to ϳ25% that of WT APP levels (Fig. 1B) . This reduction is consistent with the effects of A673T on sAPP␤ and A␤ production as we reported previously (1) .
Our findings thus far have focused on APP processing in the HEK 293 cell line. To confirm that A673T had similar effects on APP processing by BACE1 in neurons, we performed experiments in cultured primary mouse cortical neurons. Cultured neurons were transfected with cDNA encoding human APP WT, the protective A673T variant, the pathogenic APP A673V variant, or a control vector expressing ␤-gal. All constructs expressed APP at similar levels, as confirmed by quantitative PCR (data not shown). We assessed the formation of APP cleavage products A␤40, A␤42, sAPP␤, and sAPP␣ in the media of transfected cells. Our assays were designed to specifically detect cleavage products from transfected human APP constructs and did not detect endogenous mouse APP cleavage products. Similar to what was observed in HEK 293 cells, we found that the A673T APP variant generated less A␤40 and A␤42 peptides as compared with WT APP (Fig. 1, C and D) . A␤40 was reduced by 38 (Ϯ25)% and A␤42 by 35 (Ϯ10)%. APP A673V increased A␤40 and A␤42 levels by ϳ2.5-fold. Immunoassay analysis for sAPP␤ and sAPP␣ in cell supernatants (Fig. 1E ) showed that the A673T APP variant reduced the ratio of sAPP␤ relative to sAPP␣ when compared with WT APP by 49 (Ϯ5)%. Conversely, the pathogenic APP A673V variant robustly increased the sAPP␤/sAPP␣ ratio.
Overexpression of APP by transfection may result in nonphysiological processing if overexpressed substrate overwhelms endogenous proteases. Thus, we next set out to investigate APP processing of these variants when expressed at normal endogenous cellular levels. To do this, we used human iPSC lines that have been engineered via TALEN-mediated SNP alteration to carry A673T-or A673V-specific changes in APP (17) . The isogenic cell lines were differentiated into cortical neurons. The differentiated cells from the three isogenic lines appeared morphologically similar to each other and uniformly expressed APP ( Fig. 2A ). Similar to transfected mouse neurons, we observed that the A673T APP iPSC human neurons generated less A␤40 and A␤42 peptides as compared with WT APP (Fig. 2, B and C) . A␤40 was reduced by 33 (Ϯ7)% and A␤42 by 36 (Ϯ12)%. In contrast, APP A673V increased both A␤40 and A␤42 levels by ϳ2-fold. The reduction in ␤-secretase cleavage products was confirmed by measuring the ratio of sAPP␤ relative to sAPP␣ by immunoassay (Fig. 2D) . The A673T APP variant reduced the sAPP␤/sAPP␣ ratio by 32 (Ϯ18)% compared with WT APP. Conversely, the pathogenic APP A673V variant increased the sAPP␤/sAPP␣ ratio ϳ4-fold.
The consistency of our results across transfected HEK 293 cells and primary neurons and isogenic human iPSC-derived neurons confirms the strong influence of the residue at position 673 on BACE1 cleavage. The reproducible decreases in FIGURE 1. Decreased cellular production of ␤-secretase cleavage products from APP A673T. A, representative Western blot analysis of cell lysates from HEK 293 cells transfected with GFP control, WT, A673T, A673V, or K670N/M671L APP. ␣and ␤-CTF fragments were detected using an antibody specific for the C terminus of APP (A8717), and ␤-CTF fragments were specifically detected using an antibody just distal to the ␤-secretase cleavage site (6E10). An antibody to actin was used as a loading control for both blots. B, ELISA quantification of ␤-CTF cleavage product from these same cell lysates. C and D, ELISA quantification of A␤40 (C) and A␤42 (D) from supernatants of cultured mouse cortical neurons transfected with WT, A673T, or A673V human APP. E, ratio of sAPP␤/ sAPP␣ as determined by immunoassay analysis of cell supernatants from the same cortical neurons. Values represent mean Ϯ S.D. of three independent experiments, each with technical replicates. Two-tailed t test was compared with WT APP; *, p Ͻ 0.05; **, p Ͻ 0.01; ***, p Ͻ 0.001; ****, p Ͻ 0.0001. NOVEMBER 7, 2014 • VOLUME 289 • NUMBER 45 JOURNAL OF BIOLOGICAL CHEMISTRY 30993 ␤-secretase cleavage of APP across these different cell types suggest that similar alterations in APP processing likely occur in neurons in the human brain.
BACE1 Cleavage and A␤ Aggregation of a Protective APP Allele
A673T Decreases the V max of APP Processing by BACE1-Previously, we demonstrated that the A673T mutation decreased catalytic cleavage of an APP substrate by BACE1 in a reconstituted in vitro enzyme assay (1) . Here, we investigated the mechanism by which the mutation at this residue modulated BACE1 enzymatic activity. First, by utilizing TR-FRET detection against long (27 amino acids) APP peptide substrates, we demonstrated that the A673T variant displayed ϳ50% reduced cleavage activity relative to the WT substrate ( Fig. 3A) , consistent with our previous results determined by mass spectrometric detection. In comparison, the A673V mutation appeared to be a better substrate for BACE1 with an estimated 3-fold increase in cleavage rate relative to WT APP peptides at 5 M substrate concentration. When the mutations at Ala-673 were combined with the Swedish APP mutation (K670N/ M671L, Swe), the same differential modulations of BACE1 activity by threonine and valine were observed (Fig. 3B) , however with much more rapid kinetics as a result of the Swe mutations.
Utilizing a fluorogenic FRET substrate that spanned from P4 to P5Ј of the APP BACE1 cleavage sequence, the kinetic parameters of WT APP were compared with the A673T and A673V mutations. The results showed that A673T decreased and A673V increased the V max , but neither altered the K m value, suggesting that mutations at this residue have an impact on the catalytic turnover of the substrate instead of substrate binding affinity (Fig. 3C) .
To confirm that the mutations at Ala-673 do not modulate the binding affinity of peptide substrates to BACE1, we performed a substrate competition assay. We used the FRET peptide substrate containing the Swedish mutation as a detection method for BACE1 activity, and we titrated non-Swedish long peptides (WT, A673T, and A673V) into the BACE1 reaction. At a reaction time of 1-2 h, although the Swe FRET peptide substrate is efficiently cleaved by BACE1, the catalytic turnover of the unlabeled non-Swedish peptides by BACE1 is negligible. In other words, the non-Swedish peptides act as competitive binders to inhibit cleavage of the Swe FRET substrate in this assay setup, and their titration should yield IC 50 curves that reflect their respective binding affinities. The IC 50 values of WT, A673T, and A673V peptides were comparable with each other (ranging between 26 and 33 M), further supporting the hypothesis that the mutations at residue Ala-673 of APP do not alter their binding affinity to the BACE1-active site (Fig. 3D) .
Aggregation Level of A2T A␤ Variant Peptides Is Reduced in the Context of A␤(1-42) but Not A␤(1-40)-Our results indicate that the APP A673T variant is a less favorable substrate for BACE1 cleavage. However, the A673T variant also results in a single amino acid substitution (A2T) in A␤ peptides, and thus it could alter the properties of the A␤ peptide itself. Therefore, we compared the aggregation kinetics of synthetic WT, A2T, and A2V A␤ peptides, as both A␤(1-40) and A␤(1-42) species, by ThT incorporation and fluorescence.
As shown in Fig. 4 , A␤(1-40) peptides generally aggregate very slowly relative to A␤(1-42). However, the A2V substitution promotes a significant increase in both the aggregation kinetics and the extent of aggregation in A␤(1-40) (Fig. 4A) . This result is similar to observations reported by Di Fede et al. (7) . By contrast, aggregation kinetics for WT and A2T A␤(1-40) were indistinguishable from each other. When A2V A␤-(1-40) peptides were combined with WT A␤(1-40) or A2T A␤(1-40) peptides in a 1:1 ratio, we observed intermediate rates and levels of aggregation.
When assessing A␤(1-42) aggregation kinetics (Fig. 4B) , we observed similar profiles between WT A␤(1-42) and A2V A␤(1-42) peptides. In comparison, A2T A␤(1-42) showed a reproducibly lower level of aggregation than WT A␤(1-42). Mixtures of A2T A␤(1-42) with either WT A␤(1-42) or A2V A␤(1-42) showed intermediate levels of aggregation.
In vivo, A␤ peptides exist as a heterogeneous mixture. As an approximate representation of this heterogeneity, we looked at aggregation kinetics of a mixture of A␤(1-42) and A␤(1-40) in a 1:9 ratio, representative of what has been observed in human CSF (18) . When mixed together in this manner, we observed aggregation kinetics intermediate between those with pure A␤(1-40) or A␤(1-42) peptides (Fig. 4C) . The A2V peptide mixture again showed the most rapid kinetics. The A2T mixture showed slower kinetics than the WT mixed peptides in two of three experiments, and similar kinetics in the third. Mixing A2T with WT A␤ in this context results in an aggregation profile similar to WT A␤ alone.
Taken together, these results suggest that substitutions at position 2 in A␤ peptides can impact peptide aggregation properties. The most dramatic effect is with A2V substitution in the context of A␤ . This mutation appears to convert A␤(1-40) into a much more aggregation-prone molecule with A␤(1-42)-like properties. However, A2V did not alter aggregation in the context of A␤(1-42), likely because this longer peptide is already very aggregation-prone. In contrast, A2T does not appear to alter A␤(1-40) aggregation, but it does reduce the aggregation level of A␤ . When A␤(1-42) and A␤ are mixed together in a physiologically relevant ratio of 1:9, the A2T variant overall has slightly slower aggregation kinetics compared with WT. However, the resulting aggregation of A2T remains substantial, making it difficult to predict the impact of this mutation on pathological amyloid accumulation, particularly in heterozygous carriers.
Microglial Uptake of A2T A␤(1-42) Synthetic Peptides Is Reduced in Comparison with WT A␤ Peptides-Many recent Alzheimer genetic hits, including TREM2 and CD33, highlight the importance of microglial biology in Alzheimer disease (19 - 
22
). Microglial uptake of soluble A␤ is believed to be an important clearance mechanism in the brain (23) . We wondered whether the different A␤ variants we have examined might be differentially taken up by microglia. We used enriched primary microglial cultures to assess uptake of synthetic WT, A2T, and A2V A␤ peptides. Again, we assessed both A␤(1-40) and A␤(1-42) peptides prepared as oligomers. Microglia were incubated with 1 M A␤ oligomers for 90 min, after which cells were fixed, and internalized A␤ was visualized by immunocytochemistry.
As shown in Fig. 5A , A␤ could be visualized inside microglia under all conditions. However, when quantified (Fig. 5B) , it was clear that WT A␤(1-42) was internalized to a much greater extent than WT A␤(1-40). This likely reflects the higher level of aggregation with WT A␤(1-42) compared with WT A␤(1-40), because aggregation stimulates microglial internalization of extracellular debris (including A␤). A similar trend is seen when comparing the A2T peptides (Fig. 5A, middle panels) ; low levels of A2T A␤(1-40) are internalized, although significantly higher levels of A2T A␤(1-42) are taken up. However, the average A␤ fluorescence in cells treated with A2T A␤(1-42) is approximately half that of cells treated with WT A␤ . This correlates with the reduced overall aggregation of A2T A␤(1-42) relative to WT (Fig. 4B) . Interestingly the A2V peptides were internalized at high levels both as A␤(1-40) and A␤(1-42) species. This likely reflects the higher aggregation state of A2V A␤(1-40) (see Fig. 4A ), thereby resulting in behavior more like an A␤(1-42) peptide.
In conclusion, our results suggest that microglial internalization of the different A␤ variants we assayed is highly correlated with the aggregation properties of that variant. There do not appear to be any further inherent differences between the ability of microglia to internalize the A␤ variants.
Cellular Toxicity of A2T A␤ Synthetic Peptides Does Not Differ from That of WT A␤ Peptides-A␤ peptides are believed to be toxic to neurons, and at high concentrations can induce cell death in vitro. To investigate the impact of the A2T substitution on A␤ toxicity, we treated neuronal cultures with synthetic WT, A2T, and A2V A␤ peptides, both in the context of A␤(1-40) and A␤ . Mixed primary cortical cultures were incubated with the different synthetic peptides ranging in concentration from 0.1 to 10 M for 3 days, at which time cellular toxicity was assessed using a luminescent viability assay. For both A␤(1-40) and A␤(1-42), only slight toxicity was observed after treatment with the WT and A2T peptides at concentrations up to 3 M (Fig. 6) . Notably, A2V peptides showed no toxicity at these concentrations. At 10 M, all A␤(1-40) and A␤(1-42) peptides were somewhat toxic, reducing cell viability by ϳ20 -40%, regardless of the nature of the variant at position 2 of A␤.
Comparing across the full concentration range, toxicity from A2T peptides was not significantly different from WT peptides.
However, A2V peptides, both A␤(1-40) and A␤(1-42), were overall less toxic than WT peptides across the concentration range, and this difference was significant (p Ͻ 0.05 for A␤ and p Ͻ 0.001 for A␤(1-42), two-way analysis of variance). However, the effect size was small. These results seem somewhat counterintuitive, as the pathogenic peptide might be expected to be more toxic. However, it has been proposed that low molecular weight oligomers are cytotoxic to cultured neurons. It is possible that fewer of these smaller oligomers are present in the rapidly aggregating A2V peptide preparations. Furthermore, an experimental system such as ours that requires application of high concentrations of synthetic peptides to cultured neurons to elicit any toxicity may not be a good model of the disease state (24) . Nonetheless, these results suggest that the A␤ peptides produced by the A673T APP variant are no less or no more toxic than WT A␤.
DISCUSSION
The results from our biochemical and cellular analyses of the A673T APP variant support the conclusion that a likely mechanism for protection is via reduced APP cleavage, leading to decreased A␤ production over the lifetime of an A673T carrier. We demonstrate that the reduction in amyloidogenic processing of APP can be replicated across transfected cell lines and FIGURE 5 . Microglial uptake of WT, A2T, or A2V A␤ peptides. A, primary microglial cultures were incubated with WT, A2T, or A2V mutants of either A␤(1-40) (upper panels) or A␤(1-42) (lower panels) for 90 min. Microglia were then fixed and stained for Iba1 (red), DAPI (blue), and A␤ (green). Representative confocal images for each condition show that A␤(1-42) peptides accumulate in microglia to a greater extent compared with A␤(1-40). Scale bar, 10 M. B, quantification of internalized A␤ as measured by average immunofluorescence signal intensity. Values represent mean Ϯ S.D. of three independent experiments, each analyzing Ͼ10 cells per condition). Two-tailed t test, compared with WT A␤; *, p Ͻ 0.05. a.u., arbitrary units. primary neurons, as well as in isogenic human iPSC-derived neurons that express APP at endogenous levels. Mechanistically, we show that A673T reduces the catalytic turnover of APP by BACE1, whereas an alternative residue, A673V, at the same site increases the catalytic turnover rate by BACE1. Neither residue alters the affinity of APP for BACE1. Therefore, the residue at the Ala-673 site is a critical determinant of amyloidogenic processing of APP at both the enzyme and cellular level.
An alternative model, consistent with reduction in APP processing, is that protection is conferred by reduced production of ␤-CTFs and/or soluble APP␤. We observe that both ␤-CTFs and soluble APP␤ are reduced in A673T-expressing cells ( Figs. 1 and 2) . This possibility is supported by reports that suggest a role for these APP products in mediating neuronal toxicity (25) (26) (27) . Nevertheless, because of the observation that mutations in APP center on the production and/or aggregation potential of A␤ (for example, the Dutch APP mutation E693Q causes A␤ to aggregate on blood vessels causing hereditary cerebral hemorrhage with amyloidosis (28 -30)), combined with the paucity of mutations in APP directly in the cytoplasmic (␤-CTFs) or N-terminal (soluble APP␤) region of APP that alter the risk for Alzheimer disease, the most plausible hypothesis is that A␤ mediates disease.
We next investigated the aggregation properties of A␤, comparing the Ala-673 variants. We observed the greatest effect with A2V in A␤(1-40), leading to enhanced aggregation, similar to previous reports (7) . However, A2V A␤(1-42) aggregation is not altered, likely because A␤(1-42) aggregates so readily even in WT A␤(1-42) form. Conversion of A␤(1-40) to A␤(1-42) aggregation-prone behavior could easily explain pathology in A673V carriers, because A␤(1-40) is ϳ10 -20fold more abundant than A␤(1-42) in human CSF (18) . Indeed, a 1:9 mixture of A␤(1-42)/A␤(1-40) showed increased aggregation kinetics for A2V peptides relative to WT peptides. Our results with A2V peptides confirm previously reported findings relative to A␤(1-40) (7) ; however, we were not able to replicate the "heterozygous protection" proposed upon mixing WT and A2V peptides.
Of note, we also observed a consistent reduction in aggregation level of A2T peptides compared with WT peptides for A␤(1-42) but not for A␤ . When comparing a 1:9 mixture of A␤(1-42)/A␤(1-40), the A2T peptides display slightly slower aggregation kinetics compared with WT peptides. An equimolar mixture of WT and A2T peptides prepared in a 1:9 ratio of A␤(1-42)/A␤(1-40) behaved identically to WT peptides (Fig. 4C ). This in vitro experiment is our closest approximation of the A␤ species that might be present in an A673T heterozygous individual. As such, the reduced aggregation of the A2T A␤(1-42) peptides likely translates to a small impact on amyloid deposition in vivo. Nevertheless, this may contribute in part to genetic protection by the A673T variant, in combination with the substantial reduction in A␤ generation.
Interestingly, the results of our microglial uptake assay correlated directly with the aggregation results. Because microglia are known to internalize aggregated proteins, this outcome is not surprising. These data confirm our findings that A2V increases aggregation in the context of A␤(1-40), and A2T reduces aggregation in the context of A␤(1-42), functionally leading to increased and decreased microglial internalization, respectively. However, we failed to detect any other fundamental differences in how microglia recognize and engulf the variant peptides. Thus, microglial uptake of these different variants in vivo is likely to be driven purely by A␤ levels and extent of aggregation.
Our cell toxicity data suggest that the A673T variant does not confer protection against AD by generating an A␤ peptide that is inherently less toxic than WT A␤. However, toxicity assays involving A␤ are highly artificial and must be interpreted with caution (24) . As an illustration of the potential inconsistencies of these types of experiments, previous studies investigating the toxicity of the A673V variant suggested that A2V showed increased cellular toxicity (7) ; in contrast, we show that A2V may be slightly less toxic in vitro. Rather than draw spurious conclusions from these results, we simply suggest caution in over-interpreting A␤-induced cellular toxicity results.
We previously reported that the A673T variant is equally protective in apoE4 carriers and noncarriers (1); thus, the relative protective effect of the A673T variant is substantially more robust in apoE4 carriers. Taking into consideration that apoE4 carriers are considerably more likely to accumulate amyloid, and thus generate amyloid plaques and develop AD (31) (32) (33) , the findings reported herein further support the hypothesis that apoE4 is mediating its effects via A␤. Specifically, the protective A673T APP variant that reduces amyloid production and may also reduce A␤ aggregation results in a determining factor for the risk of developing AD, negating any apoE genotype effect.
We investigated several mechanisms by which A673T may confer protection against AD. The most compelling mechanism supported by our studies is that this variant reduces BACE1-mediated processing of APP. We observed this result reproducibly across multiple cell models. In addition, we found that A2T peptides are less prone to aggregation in the context of A␤(1-42) but not in the context of A␤ . In terms of translating these findings to humans, our results predict that a heterozygote A673T carrier will have a significant, but relatively moderate, reduction in A␤ production (ϳ20%). The rare nature of this mutation has made it difficult to examine endogenous A␤ levels in carriers, although attempts to do so are ongoing. In heterozygote A673T carriers, we predict that A␤ aggregation and amyloid formation will be similar or slightly reduced when compared with WT individuals. However, any resulting reduction in A␤ aggregation may work additively, or even synergistically, with reduced A␤ levels to lessen AD risk in carriers. Although it is unclear how early A␤ reduction is needed to provide protection from AD, these mechanistic studies of human APP variants further validate efforts to reduce A␤ production and aggregation as therapeutic approaches to treat Alzheimer disease.
